Table 1.
Demographic, clinical, and treatment characteristics according to the outcome of COVID-19 patients.
| Characteristics | Total | Alive patients | Deceased patients | p |
|---|---|---|---|---|
| n = 599 | n = 441 (75.8%) | n = 141 (24.2%) | ||
| Age | 0.0001 | |||
| Median (IQR) | 56 (45–66) | 54 (44–64) | 62.5 (48–70) | |
| Sex | 0.002 | |||
| Female | 355 (59.3) | 278 (80.3) | 68 (19.6) | |
| Male | 244 (40.7) | 163 (69.1) | 73 (30.9) | |
| ECOG | 0.0001 | |||
| High functionality | 342 (68.4) | 292 (87.9) | 40 (12.0) | |
| Low functionality | 158 (31.6) | 73 (48.3) | 78 (51.6) | |
| Unknown | 99 (16.5) | 76 (76.8) | 23 (23.2) | |
| Tobacco use | 0.033 | |||
| No | 442 (73.8) | 335 (78.4) | 92 (21.5) | |
| Yes | 151 (25.2) | 104 (69.8) | 45 (30.2) | |
| Unknown | 6 (1.0) | 2 (33.3) | 4 (66.7) | |
| Diabetes mellitus | 0.01 | |||
| No | 451 (75.3) | 348 (79.3) | 91 (20.7) | |
| Yes | 117 (19.5) | 76 (67.9) | 36 (32.1) | |
| Unknown | 31 (5.2) | 17 (54.8) | 14 (45.2) | |
| Chronic kidney disease | 0.001 | |||
| No | 544 (90.8) | 413 (78.2) | 115 (21.8) | |
| Yes | 24 (4.0) | 11 (47.8) | 12 (52.2) | |
| Unknown | 31 (5.2) | 17 (54.8) | 14 (45.2) | |
| Cancer status | 0.013 | |||
| Active disease | 432 (72.1) | 304 (72.9) | 113 (27.1) | |
| Disease in remittance | 146 (24.4) | 123 (84.8) | 22 (15.2) | |
| Unknown | 21 (3.5) | 14 (70.0) | 6 (30.0) | |
| Clinical stage | 0.0001 | |||
| Non-advanced | 309 (60.1) | 253 (83.2) | 51 (16.8) | |
| Advanced | 205 (39.2) | 137 (69.2) | 61 (30.8) | |
| Not available | 85 (14.2) | 51 (63.7) | 29 (36.2) | |
| Oncologic diagnosis | 0.020 | |||
| Solid tumors | 496 (82.8) | 375 (77.6) | 108 (22.4) | |
| Hematologic | 103 (17.2) | 66 (66.7) | 33 (33.3) | |
| Type of treatment | 0.0001 | |||
| With treatment | 338 (64.4) | 233 (71.7) | 92 (28.3) | |
| Without treatment | 187 (35.6) | 161 (86.6) | 25 (13.4) | |
| COVID-19 symptoms | ||||
| Cough | 0.0001 | |||
| No | 231 (38.6) | 201 (87.0) | 30 (13.0) | |
| Yes | 345 (57.6) | 227 (69.2) | 101 (30.8) | |
| Unknown | 23 (3.8) | 13 (56.5) | 10 (43.5) | |
| Fever | 0.0001 | |||
| No | 239 (39.9) | 208 (87.0) | 31 (13.0) | |
| Yes | 341 (56.9) | 224 (69.2) | 100 (30.9) | |
| Unknown | 19 (3.2) | 9 (47.4) | 10 (52.6) | |
| Dyspnea | 0.0001 | |||
| No | 331 (55.3) | 302 (91.8) | 27 (8.1) | |
| Yes | 242 (40.4) | 123 (54.2) | 104 (45.8) | |
| Unknown | 26 (4.3) | 16 (61.5) | 10 (38.5) | |
| Nausea | 0.025 | |||
| No | 445 (74.3) | 340 (78.9) | 91 (21.1) | |
| Yes | 60 (10.0) | 34 (58.6) | 24 (41.4) | |
| Unknown | 94 (15.7) | 67 (72.0) | 26 (28.0) | |
| Vomiting | 0.002 | |||
| No | 496 (82.8) | 376 (78.2) | 104 (21.7) | |
| Yes | 38 (6.3) | 20 (54.0) | 17 (45.9) | |
| Unknown | 65 (10.8) | 45 (69.2) | 20 (30.8) | |
| Abdominal pain | 0.001 | |||
| No | 465 (77.6) | 356 (78.9) | 95 (21.1) | |
| Yes | 68 (11.3) | 39 (60.0) | 26 (40.0) | |
| Unknown | 66 (11.0) | 46 (69.7) | 20 (30.3) | |
| Rhinorrhea | 0.003 | |||
| No | 462 (77.1) | 355 (79.1) | 94 (20.9) | |
| Yes | 109 (18.2) | 68 (64.8) | 37 (35.2) | |
| Unknown | 28 (4.7) | 18 (64.3) | 10 (35.7) | |
| Myalgia | 0.026 | |||
| No | 345 (57.6) | 265 (79.8) | 67 (20.2) | |
| Yes | 230 (38.4) | 162 (71.7) | 64 (28.3) | |
| Unknown | 24 (4.0) | 14 (58.3) | 10 (41.7) | |
| Arthralgia | 0.005 | |||
| No | 381 (63.6) | 294 (80.3) | 72 (19.7) | |
| Yes | 152 (25.4) | 101 (67.3) | 49 (32.7) | |
| Unknown | 66 (11.0) | 46 (69.7) | 20 (30.3) | |
| Oxygen saturation (%) | 90 (84–95) | 93 (89–95) | 80 (70–87) | 0.00001 |
COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range.
Information was not complete for some categories; therefore, the total amount may not be reached in all cases.